Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Chubb
Julphar
Federal Trade Commission
Dow
Express Scripts
Citi
Colorcon
Argus Health
Merck

Generated: January 19, 2018

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

Summary for Abbvie
International Patents:1454
US Patents:89
Tradenames:78
Ingredients:65
NDAs:90
Drug Master File Entries: 1

Drugs and US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie ANDROGEL testosterone GEL;TRANSDERMAL 022309-002 Sep 7, 2012 AB2 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie ANDROGEL testosterone GEL, METERED;TRANSDERMAL 022309-001 Apr 29, 2011 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie MAVIK trandolapril TABLET;ORAL 020528-002 Apr 26, 1996 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc TECHNIVIE ombitasvir; paritaprevir; ritonavir TABLET;ORAL 207931-001 Jul 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie PARADIONE paramethadione CAPSULE;ORAL 006800-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie CALCIJEX calcitriol INJECTABLE;INJECTION 018874-002 Sep 25, 1986 ➤ Subscribe ➤ Subscribe
Abbvie MAVIK trandolapril TABLET;ORAL 020528-003 Apr 26, 1996 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020708-001 Mar 7, 1997 ➤ Subscribe ➤ Subscribe
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT-PED leuprolide acetate INJECTABLE;INJECTION 020263-002 Apr 16, 1993 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-001 Dec 22, 1995 ➤ Subscribe ➤ Subscribe
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-002 May 30, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 6/19/2014
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 6/19/2013
➤ Subscribe Capsules 100 mg ➤ Subscribe 10/31/2012
➤ Subscribe Gel 1.62% ➤ Subscribe 4/6/2012
➤ Subscribe Tablets 100 mg ➤ Subscribe 12/21/2010
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 12/6/2010
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 5/10/2010
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 9/2/2009
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 9/1/2009
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 8/12/2009
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 8/4/2009
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 12/23/2008
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 12/19/2008
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 11/28/2008
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 10/14/2008
➤ Subscribe Capsules 4 mcg ➤ Subscribe 8/25/2008
➤ Subscribe Tablets 48 mg ➤ Subscribe 7/1/2008
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2/20/2008
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 11/9/2007
➤ Subscribe Tablets 145 mg ➤ Subscribe 10/19/2007
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 7/24/2007
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2/24/2006
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 5/27/2005
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2/8/2005
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 10/4/2004
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 5/3/2004

Non-Orange Book US Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,937,150 Anti-viral compounds ➤ Subscribe
8,716,454 Solid compositions ➤ Subscribe
9,394,279 Anti-viral compounds ➤ Subscribe
7,521,068 Dry powder aerosols of nanoparticulate drugs ➤ Subscribe
6,162,443 Container for an inhalation anesthetic ➤ Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles ➤ Subscribe
6,677,492 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid ➤ Subscribe
6,472,529 Retroviral protease inhibiting compounds ➤ Subscribe
8,332,661 Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices ➤ Subscribe
9,452,194 Methods for treating HCV ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Abbvie Drugs

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
668 Luxembourg ➤ Subscribe PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2015012 Lithuania ➤ Subscribe PRODUCT NAME: OMBITASVIRUM; REGISTRATION NO/DATE: EU/1/14/982 20150115
C/GB07/011 United Kingdom ➤ Subscribe PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2015 00014 Denmark ➤ Subscribe PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
C0013 France ➤ Subscribe PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2013025,C1304992 Lithuania ➤ Subscribe PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
0443983/03 Switzerland ➤ Subscribe PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0005 Belgium ➤ Subscribe PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
90012-9 Sweden ➤ Subscribe PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
15/009 Ireland ➤ Subscribe PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Harvard Business School
UBS
Deloitte
Fuji
McKinsey
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot